Franklin 1 · protein crystallization

Neurological and metabolic disorders

Two existing briefs sit under this tag: ADHD (neurological) and diabetes (metabolic). ADHD is a large formulation and crystallization gap, not a leading cause of death. Diabetes is, and that brief carries the mortality numbers. Both are crystallization and formulation problems for Franklin 1.

ADHD: small-molecule actives with almost no published microgravity crystallization work. Diabetes: insulin already has a space crystal history; GLP-1s and oral agents still lack high-cadence free-flying process maps.

Open the ADHD or diabetes brief for the full public version. Same payload: sealed dual-reservoir, mixing, thermal control, optical data. Pathfinder targeted 2027.

Neurological + metabolic scale · 2025 public reports

ADHD medicines$14–22B
Diabetes medicines$75–100B+

Both sit under this tag as crystallization and formulation problems. GLP-1 (diabetes + obesity) is on the order of $100B+ combined in recent reports.

Download ADHD research brief (PDF)Download diabetes research brief (PDF)